Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer

Aptamers provide a potential source of alternative targeting molecules for existing antibody diagnostics and therapeutics. In this work, we selected novel DNA aptamers targeting the HER2 receptor by an adherent whole-cell SELEX approach. Individual aptamers were identified by next generation sequenc...

Full description

Saved in:
Bibliographic Details
Main Authors: Marlies Gijs (Author), Gregory Penner (Author), Garth B. Blackler (Author), Nathalie R.E.N. Impens (Author), Sarah Baatout (Author), André Luxen (Author), An M. Aerts (Author)
Format: Book
Published: MDPI AG, 2016-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_360cb41a0c2d4a4f95cb765536aee994
042 |a dc 
100 1 0 |a Marlies Gijs  |e author 
700 1 0 |a Gregory Penner  |e author 
700 1 0 |a Garth B. Blackler  |e author 
700 1 0 |a Nathalie R.E.N. Impens  |e author 
700 1 0 |a Sarah Baatout  |e author 
700 1 0 |a André Luxen  |e author 
700 1 0 |a An M. Aerts  |e author 
245 0 0 |a Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer 
260 |b MDPI AG,   |c 2016-05-01T00:00:00Z. 
500 |a 1424-8247 
500 |a 10.3390/ph9020029 
520 |a Aptamers provide a potential source of alternative targeting molecules for existing antibody diagnostics and therapeutics. In this work, we selected novel DNA aptamers targeting the HER2 receptor by an adherent whole-cell SELEX approach. Individual aptamers were identified by next generation sequencing and bioinformatics analysis. Two aptamers, HeA2_1 and HeA2_3, were shown to bind the HER2 protein with affinities in the nanomolar range. In addition, both aptamers were able to bind with high specificity to HER2-overexpressing cells and HER2-positive tumor tissue samples. Furthermore, we demonstrated that aptamer HeA2_3 is being internalized into cancer cells and has an inhibitory effect on cancer cell growth and viability. In the end, we selected novel DNA aptamers with great potential for the diagnosis and possible treatment of HER2-positive cancer. 
546 |a EN 
690 |a aptamer 
690 |a DNA 
690 |a HER2 
690 |a diagnosis 
690 |a therapeutics 
690 |a cancer 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 9, Iss 2, p 29 (2016) 
787 0 |n http://www.mdpi.com/1424-8247/9/2/29 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/360cb41a0c2d4a4f95cb765536aee994  |z Connect to this object online.